Your browser doesn't support javascript.
loading
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Sum, Eva; Rapp, Moritz; Fröbel, Philipp; Le Clech, Marine; Dürr, Harald; Giusti, Anna Maria; Perro, Mario; Speziale, Dario; Kunz, Leo; Menietti, Elena; Brünker, Peter; Hopfer, Ulrike; Lechmann, Martin; Sobieniecki, Andrzej; Appelt, Birte; Adelfio, Roberto; Nicolini, Valeria; Freimoser-Grundschober, Anne; Jordaan, Whitney; Labiano, Sara; Weber, Felix; Emrich, Thomas; Christen, François; Essig, Birgit; Romero, Pedro; Trumpfheller, Christine; Umaña, Pablo.
Afiliación
  • Sum E; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Rapp M; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany.
  • Fröbel P; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Le Clech M; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Dürr H; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany.
  • Giusti AM; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Perro M; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Speziale D; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Kunz L; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Menietti E; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Brünker P; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Hopfer U; Roche Innovation Center Basel (RICB), pRED, Basel, Switzerland.
  • Lechmann M; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany.
  • Sobieniecki A; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Appelt B; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Adelfio R; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Nicolini V; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Freimoser-Grundschober A; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Jordaan W; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland.
  • Labiano S; Department of Fundamental Oncology, University of Lausanne, Epalinges, Switzerland.
  • Weber F; Roche Innovation Center Basel (RICB), pRED, Basel, Switzerland.
  • Emrich T; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany.
  • Christen F; Roche Innovation Center Basel (RICB), pRED, Basel, Switzerland.
  • Essig B; Roche Innovation Center Munich (RICM), pRED, Penzberg, Germany.
  • Romero P; Department of Fundamental Oncology, University of Lausanne, Epalinges, Switzerland.
  • Trumpfheller C; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland. pablo.umana@roche.com christine.trumpfheller@roche.com.
  • Umaña P; Roche Innovation Center Zurich (RICZ), Roche Pharmaceutical Research and Early Development (pRED), Schlieren, Switzerland. pablo.umana@roche.com christine.trumpfheller@roche.com.
Clin Cancer Res ; 27(14): 4036-4053, 2021 07 15.
Article en En | MEDLINE | ID: mdl-33771854
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Endopeptidasas / Antígenos CD40 / Antineoplásicos Inmunológicos / Inmunoterapia / Proteínas de la Membrana / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Endopeptidasas / Antígenos CD40 / Antineoplásicos Inmunológicos / Inmunoterapia / Proteínas de la Membrana / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos